SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Provectus Pharmaceuticals Inc.
PVCT 0.0650+0.2%Nov 18 12:36 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: NTTG6/10/2013 7:42:08 PM
1 Recommendation

Recommended By
Pogeu Mahone

  Read Replies (1) of 13111
 
WOW....Lenvatinib doubles progression free survival in chemo naive stage IV melanoma compared to dacarbazine alone.........head to head trial, 2.7 fold improvement in PFS, p value of 0.0033, stage IV melanoma, works in BRAF wild type patient too, all that from a PII trial design...OMG.....they confirmed their proof of concept and head to head in a PII trial....now that is data an investor can sink their teeth into.

Oh, look...several dose ranging studies already done, a combination study with temozolomide already done, a study in unresectable stage III and IV is done recruiting, and PIII in HCC vs (not with) sorafenib is already underway.

sigh, if only
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News